CA2802931C - Novel glucagon like peptide analogs, composition, and method of use - Google Patents

Novel glucagon like peptide analogs, composition, and method of use Download PDF

Info

Publication number
CA2802931C
CA2802931C CA2802931A CA2802931A CA2802931C CA 2802931 C CA2802931 C CA 2802931C CA 2802931 A CA2802931 A CA 2802931A CA 2802931 A CA2802931 A CA 2802931A CA 2802931 C CA2802931 C CA 2802931C
Authority
CA
Canada
Prior art keywords
group
amino acid
acid
glp
histidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2802931A
Other languages
English (en)
French (fr)
Other versions
CA2802931A1 (en
Inventor
Shaojing Hu
Fenlai Tan
Yanping Wang
Cunbo Ma
Yunyan Hu
Hong Cao
Xiangdong Zhao
Wei LONG
Yinxiang Wang
Lieming Ding
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Betta Pharmaceuticals Co Ltd
Original Assignee
Betta Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betta Pharmaceuticals Co Ltd filed Critical Betta Pharmaceuticals Co Ltd
Publication of CA2802931A1 publication Critical patent/CA2802931A1/en
Application granted granted Critical
Publication of CA2802931C publication Critical patent/CA2802931C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
CA2802931A 2010-05-17 2010-05-17 Novel glucagon like peptide analogs, composition, and method of use Active CA2802931C (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2010/000692 WO2011143788A1 (en) 2010-05-17 2010-05-17 Novel glucagon like peptide analogs, composition, and method of use

Publications (2)

Publication Number Publication Date
CA2802931A1 CA2802931A1 (en) 2011-11-24
CA2802931C true CA2802931C (en) 2016-10-04

Family

ID=44991143

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2802931A Active CA2802931C (en) 2010-05-17 2010-05-17 Novel glucagon like peptide analogs, composition, and method of use

Country Status (13)

Country Link
US (1) US9487570B2 (https=)
EP (1) EP2571897B1 (https=)
JP (1) JP5819946B2 (https=)
KR (1) KR101609302B1 (https=)
CN (1) CN103124739B (https=)
AU (1) AU2010353685B2 (https=)
BR (1) BR112012029248B1 (https=)
CA (1) CA2802931C (https=)
ES (1) ES2528496T3 (https=)
RU (1) RU2557301C2 (https=)
SG (1) SG185604A1 (https=)
WO (1) WO2011143788A1 (https=)
ZA (1) ZA201209566B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012027545B1 (pt) * 2010-04-27 2020-09-24 Betta Pharmaceuticals Co., Ltd. Composto, composição farmacêutica, uso da composição farmacêutica e uso de um composto
KR20140121449A (ko) * 2012-01-24 2014-10-15 유니버시티 오브 매사추세츠 췌장 베타-세포 장애에서의 가용성 ｍａｎｆ
WO2019082138A1 (en) * 2017-10-27 2019-05-02 Lorven Biologics Private Limited PROCESS FOR THE PREPARATION OF LIRAGLUTIDE USING RECOMBINANT SACCHAROMYCES CEREVISIAE
WO2020118843A1 (zh) * 2018-12-12 2020-06-18 四川利通科创生物医药科技有限公司 一种glp-1突变体及其制备方法和用途
CN112898406B (zh) * 2019-10-12 2023-11-10 深圳纳福生物医药有限公司 不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用
CN110862448A (zh) * 2019-11-21 2020-03-06 浙江大学 两性离子多肽修饰的glp-1衍生物及其制备方法和应用
CN111253475B (zh) * 2020-02-18 2021-03-09 江苏诺泰澳赛诺生物制药股份有限公司 Glp-1激动多肽化合物及其盐与合成方法及用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
ATE164852T1 (de) 1990-01-24 1998-04-15 Douglas I Buckley Glp-1-analoga verwendbar in der diabetesbehandlung
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
ATE424413T1 (de) * 2000-06-16 2009-03-15 Lilly Co Eli Analoge des glucagon-ähnlichen peptids-1
CA2463908A1 (en) * 2001-10-18 2003-04-24 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
AU2002335093A1 (en) * 2001-10-19 2003-04-28 Riken Nr3b nmda receptor subunit compositions and related methods
WO2003084563A1 (en) * 2002-04-04 2003-10-16 Novo Nordisk A/S Glp-1 agonist and cardiovascular complications
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1605897B1 (en) * 2003-03-19 2012-07-25 Eli Lilly And Company Polyethelene glycol link glp-1 compounds
ATE541582T1 (de) * 2003-06-03 2012-02-15 Novo Nordisk As Stabilisierte pharmazeutische glp-1 peptid zusammensetzungen
US7538185B2 (en) * 2004-01-08 2009-05-26 Theratechnologies Inc. Glucagon-like peptide-1 analogs with long duration of action
CN100503637C (zh) * 2004-04-14 2009-06-24 浙江贝达药业有限公司 胰高血糖素样肽类似物、其组合物及其使用方法
CN100535006C (zh) * 2004-09-06 2009-09-02 上海华谊生物技术有限公司 Glp-1类似物
EA011166B1 (ru) * 2004-12-22 2009-02-27 Эли Лилли Энд Компани Композиции слитых белков-аналогов glp-1
TWI372629B (en) * 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
PT1881850E (pt) * 2005-05-13 2010-11-26 Lilly Co Eli Compostos peguilados de glp-1
BRPI0615573A2 (pt) * 2005-09-08 2011-05-24 Tufts College análogos de glp-1 estabilizados
DE102005063375A1 (de) * 2005-09-15 2007-04-19 Schülke & Mayr GmbH Antimikrobielle Zubereitungen mit einem Gehalt an Octenidindihydrochlorid verkapselt in Liposomen
ES2495741T3 (es) * 2006-04-20 2014-09-17 Amgen, Inc Compuestos de GLP-1
WO2008082656A1 (en) * 2006-12-29 2008-07-10 Ipsen Pharma S.A.S. Glp-1 pharmaceutical compositions
GB0717399D0 (en) * 2007-09-07 2007-10-17 Uutech Ltd Use of GLP-1 analogues for the treatment of disorders associated with dysfunctional synaptic transmission
WO2009030744A1 (en) * 2007-09-07 2009-03-12 Janssen Pharmaceutica Nv Combinations of pyrimethanil and silver compounds
US20100317057A1 (en) * 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues

Also Published As

Publication number Publication date
ES2528496T3 (es) 2015-02-10
WO2011143788A1 (en) 2011-11-24
SG185604A1 (en) 2012-12-28
JP2013527178A (ja) 2013-06-27
CN103124739A (zh) 2013-05-29
JP5819946B2 (ja) 2015-11-24
CA2802931A1 (en) 2011-11-24
BR112012029248B1 (pt) 2021-09-28
US20130203672A1 (en) 2013-08-08
US9487570B2 (en) 2016-11-08
KR20130039740A (ko) 2013-04-22
KR101609302B1 (ko) 2016-04-06
RU2012154322A (ru) 2014-06-27
CN103124739B (zh) 2015-11-25
ZA201209566B (en) 2013-08-28
AU2010353685B2 (en) 2014-09-25
EP2571897A1 (en) 2013-03-27
EP2571897A4 (en) 2013-11-06
AU2010353685A1 (en) 2013-01-10
AU2010353685A8 (en) 2013-05-09
BR112012029248A2 (pt) 2020-06-02
EP2571897B1 (en) 2014-11-05
RU2557301C2 (ru) 2015-07-20

Similar Documents

Publication Publication Date Title
ES2672770T3 (es) Derivados del péptido-1 similar al glucagón y su uso farmacéutico
JP5755398B2 (ja) 伸長されたｇｌｐ−１化合物
US9012398B2 (en) Acylated exendin-4 compounds
US8536122B2 (en) Acylated GLP-1 compounds
US9920106B2 (en) GLP-1 compounds
US20090062192A1 (en) Dimeric Peptide Agonists of the Glp-1 Receptor
CA2802931C (en) Novel glucagon like peptide analogs, composition, and method of use
WO2009030774A1 (en) Truncated glp-1 derivatives and their therapeutical use
WO2006097535A2 (en) Peptide agonists of the glucagon family with secretin like activity
TWI428139B (zh) A novel glucagon-like peptide analogue, a composition and use thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20121116

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20241118